Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes
Open Access
- 5 July 2024
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 46 (5) , 1163-1171
Abstract
Background: The Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy (STOPPFrail) criteria aim to reduce inappropriate/unnecessary medications in frail older adults, which should minimise adverse drug events and additional healthcare expenditure. Little is known about the economic outcomes of applying these criteria as an intervention. Aim: To evaluate cost avoidance of pharmacist-led application of STOPPFrail to frail older nursing home residents with limited life expectancy. Method: Pharmacist-identified STOPPFrail-defined potentially inappropriate medications that were deprescribed by patients’ general practitioners were assigned a rating by a multidisciplinary panel, i.e. the probability of an adverse drug event occurring if the medication was not deprescribed. The intervention’s net cost benefit and cost–benefit ratio were then determined by factoring in adverse drug event cost avoidance (calculated from probability of adverse drug event ratings), direct cost savings (deprescribed medication costs/reimbursement fees), and healthcare professionals’ salaries. Results: Of the 176 potentially inappropriate medications deprescribed across 69 patients, 65 (36.9%) were rated as having a medium or high probability of an adverse drug event occurring if not deprescribed. With €27,162 for direct cost savings, €61,336 for adverse drug event cost avoidance, and €2,589 for healthcare professionals' salary costs, there was a net cost benefit of €85,909 overall. The cost–benefit ratio was 33.2 and remained positive in all scenarios in sensitivity analyses. Conclusion: Pharmacist-led application of STOPPFrail to frail older nursing home residents is associated with significant cost avoidance. Wider implementation of pharmacist interventions in frail older nursing home residents should be considered to reduce potentially inappropriate medications and patient harm, alongside substantial cost savings for healthcare systems.Keywords
All Related Versions
Funding Information
- Irish Research Council (GOIPG/2020/1070)
This publication has 40 references indexed in Scilit:
- Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysisInternational Journal of Clinical Pharmacy, 2024
- Reduction of Polypharmacy in Frail Older Patients in Hong Kong Using STOPPFrail CriteriaJournal of the American Medical Directors Association, 2023
- Identification of Potentially Inappropriate Medications in Frail Older Adults Residing in Long-Term Care: A Retrospective Chart Review StudyDrugs - Real World Outcomes, 2022
- Prophylactic Antimicrobial Prescribing in Australian Residential Aged-Care Facilities: Improvement is RequiredDrugs - Real World Outcomes, 2022
- Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studiesJournal of Clinical Epidemiology, 2014
- Costs of Adverse Drug Events in German Hospitals—A Microcosting StudyValue in Health, 2012
- The Frailty Syndrome: Definition and Natural HistoryClinics in Geriatric Medicine, 2011
- Age‐related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applicationsBritish Journal of Clinical Pharmacology, 2003
- Incidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory SettingJAMA, 2003
- Assessment of a Nursing Home Medication Review Service Provided by Hospital‐Based Clinical PharmacistsThe Australian Journal of Hospital Pharmacy, 1999